Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health Inc (OPK) maintains this comprehensive news hub for investors and healthcare professionals tracking developments in precision diagnostics and therapeutic innovation. Our curated collection features official press releases, regulatory filings, and verified third-party analysis of OPKO's advancements in genetic testing platforms and pharmaceutical research.
This resource serves as a centralized repository for monitoring strategic initiatives across OPKO's core segments: clinical diagnostics through BioReference Health laboratories, and pharmaceutical development targeting metabolic disorders and chronic conditions. Users will find updates on clinical trial progress, partnership announcements, and operational milestones within the company's global supply network.
Key content categories include earnings reports, product pipeline developments, FDA regulatory updates, and strategic business decisions. The page is regularly updated to reflect OPKO's evolving position in healthcare markets while maintaining historical context for longitudinal analysis.
Bookmark this page or set news alerts to stay informed about OPKO Health's contributions to diagnostic technology and targeted therapies. For verified information directly from corporate sources, we recommend cross-referencing filings with official SEC documentation.
OPKO Health, Inc. (NASDAQ: OPK) will announce its financial results for the first quarter of 2023 on May 3, 2023, after market close. The company plans to host a conference call and webcast to discuss the results and provide financial guidance at 4:30 p.m. Eastern time on the same day. Interested participants are encouraged to pre-register for the call to receive a unique PIN for immediate access. A replay of the call will be available until May 10, 2023. OPKO is focused on establishing leading positions in biopharmaceuticals and diagnostics through its proprietary technologies and expertise.
OPKO Health, Inc. (NASDAQ: OPK) has announced an R&D Day event scheduled for March 20, 2023, at 4:00 p.m. Eastern time. This two-hour virtual event will feature presentations from OPKO executives regarding ModeX Therapeutics' multispecific technology platforms, focusing on oncology and infectious diseases. Management will also discuss the MDX-2201 technology associated with a recently announced collaboration with Merck for a vaccine targeting Epstein-Barr virus. Attendees can access the live and archived webcast on OPKO’s Investor Relations website and participate in a Q&A session afterward.
OPKO Health announced an exclusive worldwide license and collaboration agreement with Merck for the development of MDX-2201, a preclinical nanoparticle vaccine targeting the Epstein-Barr virus (EBV). This vaccine aims to address the health challenges posed by EBV, including infectious mononucleosis and associated cancers. Under the agreement, OPKO will receive an upfront payment of $50 million and potential milestone payments totaling up to $872.5 million, in addition to royalties on global sales. The collaboration highlights ModeX's innovative multi-targeting approach and Merck's expertise in vaccine development.
OPKO Health, Inc. (NASDAQ: OPK) reported its fourth-quarter financial results for 2022, noting total revenues of $185.4 million, down from $401.3 million in 2021. The operating loss improved to $55.3 million from $63.1 million year-over-year. Significant highlights included revenue growth in pharmaceuticals, with product sales rising to $37.9 million, primarily from NGENLA® and RAYALDEE. However, diagnostics revenue plummeted to $139.4 million due to decreased COVID-19 testing. The net loss was $85.2 million, or $0.11 per share, compared to a net loss of $73.8 million in the prior year. Cash and cash equivalents stood at $153.2 million.
FAQ
What is the current stock price of Opko Health (OPK)?
What is the market cap of Opko Health (OPK)?
